Little is known for certain about the genetics of schizophrenia. The advent of genomewide association has been widely anticipated as a promising means to identify reproducible DNA sequence variation associated with this important and debilitating disorder. A total of 738 cases with DSM-IV schizophrenia (all participants in the CATIE study) and 733 group-matched controls were genotyped for 492 900 single-nucleotide polymorphisms (SNPs) using the Affymetrix 500K two-chip genotyping platform plus a custom 164K fill-in chip. Following multiple quality control steps for both subjects and SNPs, logistic regression analyses were used to assess the evidence for association of all SNPs with schizophrenia. We identified a number of promising SNPs for follow-up studies, although no SNP or multimarker combination of SNPs achieved genomewide statistical significance. Although a few signals coincided with genomic regions previously implicated in schizophrenia, chance could not be excluded. These data do not provide evidence for the involvement of any genomic region with schizophrenia detectable with moderate sample size. However, a planned genomewide association study for response phenotypes and inclusion of individual phenotype and genotype data from this study in meta-analyses hold promise for eventual identification of susceptibility and protective variants.
Introduction
In the past several decades, it has become generally accepted that schizophrenia (SCZ) is a complex trait with a substantial genetic component. The accumulated evidence suggests that SCZ is a relatively common disorder with a lifetime morbid risk of 0.72%. 1, 2 Genetic factors have been strongly and consistently implicated via family, adoption and twin studies. 3, 4 A meta-analytic estimate of the broad-sense heritability 5 of SCZ was 81% (95% CI (confidence interval): 73-90%) 4 and the recurrence risk to siblings (l sibs ) 6 was 8.55 (95% CI: 7.86-9.57) in a populationbased Swedish national sample of over 7.7 million individuals, 2 consistent with prior estimates. 3 These results have been used in support of the application of an array of linkage and association methods 7 attempting to identify genomic regions that confer risk for or protection against the development of SCZ. These efforts have been considerable: we have identified 31 independent samples in which genomewide linkage has been applied (3108 multiplex SCZ pedigrees and over 8. Despite these efforts, little is known for certain about the genetics of SCZ. The genomewide linkage studies have not converged to identify a set of highpriority genomic regions; 8 indeed, no genomic region has been implicated in more than 4 of 31 genomewide linkage studies and a perhaps implausibly large 58% of the genome has been implicated at least once. The accumulated evidence for specific candidate genes, such as NRG1, 9,10 DTNBP1 11,12 or DISC1, 13 does not constitute unequivocal and consistent replication. 14 These findings stand in contrast to other results in human complex-trait genetics-for example, genetic variation in intron 1 FTO was associated with body mass index in 13 cohorts and 38 759 individuals with remarkable consistency. 15 The possibility that all members of a consensus set of the best candidate genes for SCZ are false-positives has not been convincingly excluded.
In the past 2 years, the widely anticipated method of genomewide association study (GWAS) has become technically and economically feasible. These studies entail individual genotyping of considerable numbers of cases and controls for 100 000 or more genetic markers (single-nucleotide polymorphisms (SNPs)). Evident successes in identifying highly compelling candidate genes for age-related macular degeneration, 16 body mass index, 15 inflammatory bowel disease, 17 ,18 type 1 diabetes mellitus 18 and type 2 diabetes mellitus [19] [20] [21] [22] support the utility of GWAS. To date, two GWAS that employed individual genotyping have been published for psychiatric disorders-a small study of SCZ 23 and the Wellcome Trust Case-Control Consortium study of bipolar disorder. 18 Multiple GWAS are known to be in progress for attention-deficit hyperactivity disorder, autism, bipolar disorder and major depressive disorders as well as for SCZ.
In 2006, academic investigators from the NIMHfunded Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project 24, 25 entered into a scientific collaboration with Eli Lilly and Company to conduct individual GWAS genotyping and joint analyses on the CATIE samples. The collaboration contract required that genotype and phenotype data be made available to the scientific community with intellectual property rights consistent with NIH policies intended to maximize public benefit resulting from the research. The genotype and phenotype data reported here were deposited with the controlled-access repository of the NIMH in June 2007 (http://www.nimhgenetics.org (accessed 28 June 2007)).
Here, we report the primary analyses aimed at identifying SNPs associated with susceptibility to SCZ using 492 900 SNPs that were genotyped in 738 participants with SCZ and 733 group-matched controls from a US population-based sample.
Methods
We have attempted to follow the published guidelines for GWAS (Chanock et al., 26 Box 1).
Subjects
All cases were participants in the CATIE project (NIMH contract NO1 MH90001), which was conducted between January 2001 and December 2004.
CATIE was a multiphase randomized controlled trial of antipsychotic medications involving 1460 persons with SCZ followed-up for up to 18 months. 24, 27 The philosophy of the trial was to assess controlled treatment with antipsychotic drugs in a broad range of patients with SCZ under 'real-world' conditions. To maximize representativeness, subjects were ascertained from an array of clinical settings across the United States. The number of subjects evaluated was 1894, and 1460 (77.0%) entered into CATIE. No subject was known to be related to any other subject. The optional genetic substudy began about a year after the trial began and 51% of the CATIE participants donated a DNA sample.
Preliminary diagnoses were established by referring psychiatrists and final study diagnoses of DSM-IV SCZ 28 were independently established by CATIE personnel using the Structured Clinical Interview for DSM-IV, 29 including review of all available information (including psychiatric and general medical records) along with one or more subject interviews. Interviewers were experienced Master's-level clinicians who were trained to criterion via a standard protocol. 29 Any diagnostic uncertainties were resolved via discussion with one of the CATIE senior clinicians. The study inclusion criteria were as follows: definite diagnosis of SCZ, 28,29 age 18-67 years, clinical decision that oral medication was appropriate, adequate decision-making capacity and provision for written informed consent. Exclusion criteria are detailed elsewhere. 24 Briefly, patients were excluded if they had received a diagnosis of schizoaffective disorder, mental retardation or another cognitive disorder; a history of serious adverse reactions to the proposed treatments; only one psychotic episode; a history of treatment resistance (defined by the persistence of severe symptoms despite adequate trials of one of the proposed treatments or prior treatment with clozapine); if they were pregnant or breastfeeding or had a serious and unstable medical condition. Individuals with psychoactive drug-use disorders were included but only when there was positive evidence that SCZ was an independent diagnosis.
Controls were ascertained from a US nationalsampling frame as part of the NIMH Genetics repository (MH059571, PI: Dr Pablo Gejman, release v4.0, June 2006). Controls were collected by Knowledge Networks, a survey and market research company whose panel contains approximately 60 000 households ( > 120 000 unrelated adults). Households were selected via random digit dialing and proportionally from 25 major US population areas and financial incentives were provided for participation. The Knowledge Networks panel is generally representative of the US population but with a slight bias toward higher income and education. To be eligible for matching to cases, we required that potential controls deny any history of SCZ, schizoaffective disorder, bipolar disorder, auditory hallucinations and delusional beliefs. These controls are being used for multiple additional GWAS, and meta-analysts need to use caution when combining results or data across studies that use these common controls.
Case-control matching There were 3487 individuals in v4.0 of the control data set and 2645 controls were eligible for matching to CATIE cases-842 individuals were removed from consideration due to at least one of the following reasons: a self-reported possible history of a psychotic disorder (SCZ, schizoaffective disorder, bipolar disorder, delusional disorder or auditory hallucinations), age < 18 or > 67, lack of documentation of informed consent or missing data for a matching variable (age, sex or self-reported race). Cases were group-matched to controls by 5-year age band, sex and self-reported race. Most cases (91.4%) were successfully matched to controls. The exception was for 66 cases (8.6%) that could not be matched due to a deficiency of African-American males aged 18-38 years in v4.0 of the control cohort. Rather than eliminating cases, African-American females in this age band were selected as controls.
DNA sampling and cell-line establishment
Peripheral venous blood samples were sent to RUCDR (Rutgers University Cell and DNA Repository) where cell lines were established via Epstein-Barr virus transformation. RUCDR employs stringent quality control procedures and the success rate for immortalization exceeds 99%. Sample DNA concentrations were quantified and normalized via the use of Picogreen dsDNA Quantitation Kits (Molecular Probes, Eugene, OR, USA).
Ethical issues
The CATIE study was approved by the institutional review board at each site, and written informed consent was obtained from the subjects or their legal guardians (including an additional consent for genetic studies). Written informed consent was obtained from all controls. All biological samples, phenotypes and genotypes were de-identified before deposit into the NIMH/RUCDR repositories. Although the analyses described here are generally not considered to be 'human subjects research', as defined by the relevant US statutes (45 CFR part 46), this research was reviewed and approved by the Institutional Review Board at the University of North Carolina (Chapel Hill, NC, USA).
GWAS genotyping
Individual genotyping was conducted by Perlegen Sciences (Mountain View, CA, USA) using three genotyping chips: Affymetrix 500K 'A' chipset (Nsp I and Sty I chips; Santa Clara, CA, USA) 30 Fourth, the genotyping data were used to select the final set of subjects for analysis. The identity-by-state matrix for all autosomal genotypes for all pairwise combinations of subjects was generated using PLINK. 36 Four pairs of cases were cryptic duplicates and one member of each pair was removed. The numbers of heterozygous and homozygous genotypes on chrX (excluding the pseudoautosomal regions (PARs)) and chrY for each subject were counted and compared with phenotypic sex-21 subjects (3 cases and 18 controls) with sex discrepancies were removed. Twelve subjects (9 cases and 3 controls) were removed for excessive missing genotypes (X0.05). After application of these filters, there were 1471 subjects (738 cases and 733 controls).
Fifth, the final set of SNPs was selected for analysis. Beginning with the 508 286 SNPs delivered by Perlegen, 76 duplicated SNPs, 3803 SNPs with minor allele frequencies < 0.01, 9279 SNPs with missingness > 0.05362 (the 99.5th percentile in this data set) and 2272 SNPs that led to X2 disagreements in 36 pairs of duplicated samples were removed. SNPs were not excluded based solely on deviations from the Hardy-Weinberg equilibrium 37 given the ancestries of the subjects and as there are informative reasons for departures from the Hardy-Weinberg equilibrium. 38 After application of these filters, there were 492 900 SNPs for analysis (44 SNPs were excluded for multiple reasons). We investigated batch effects and found none.
Control of population stratification
Cases and controls are of mixed ancestry. Using the US census 'race' categories, 56.3% of subjects described themselves as only White, 29.6% as only Black/African-American and 14.1% selected some other or more than one racial category (that is, American-Indian/Alaska Native, Asian, Black/AfricanAmerican, Native Hawaiian/other Pacific Islander, White and Hispanic/Latino). GWAS in a sample of mixed ancestry can yield false-positive findings due to population stratification, if there are sufficiently large differences in the phenotype and genotype distributions within the strata defined by ancestry. 39, 40 There were two critical decisions in regard to the analysis of these GWAS data. First, rather than stratifying the analysis by self-reported 'race' (an imperfect proxy for ancestry), 41 the entire cohort was analyzed together to maximize statistical power. Second, the available statistical methods for population stratification control were evaluated. At least five major methods for population stratification control have been described-genomic control, 42 structured association, 43 principal components, 44 multidimensional scaling 36 and partial least squares relating phenotype to ancestry-informative markers. 45, 46 These methods were evaluated extensively using these GWAS data (for details see Supplementary Methods Part 2). Briefly, the central criteria in evaluating these methods were control of Type 1 error while preserving statistical power. To avoid bias, these comparisons were based on lists of P-values alone and were blinded to all SNP rs numbers and annotation information.
The consensus among the statistical geneticists involved in these evaluations was to use principal components 44, 47 to robustly control for stratification effects while preserving statistical power. The consensus was to use seven principal components as covariates in all logistic regression models (see Supplementary Methods Part 2). Moreover, as reported elsewhere, 18, 44 the principal components method can capture both subtle and extensive variation due to both genomic and experimental features and, with the availability of > 10 5 genetic markers, self-reported 'race' is no longer required as a proxy for ancestry. 41 The principal components method is computationally efficient and uses the genotyping matrix to infer continuous axes of genetic variation (eigenvectors), which then serve as covariates. The potential weakness of this method is lowered statistical power in some genomic regions-if an SNP is highly stratified, then it could contribute strongly to a principal component and induce collinearity. This concern is mitigated by the fact that large numbers of SNPs contribute to each principal component. All autosomal GWAS SNPs were used as input to EigenSoft (http://www.genepath.med.harvard.edu/ reich/Software.htm; v1.0 (accessed 28 June 2007)), 44, 47 and default parameters were used except that the outlier removal option was turned off to generate estimates for all subjects.
Single-marker analyses All autosomal and pseudoautosomal SNPs that passed quality control checks were tested for association with SCZ using logistic regression under a logadditive mode of inheritance (1 d.f.; each SNP coded as the number of minor alleles). All regression models included the first seven principal components as covariates to adjust for stratification and any artifacts detectable in the GWAS data. Of the different inheritance models that could be considered, logadditive model appears to minimize the number of comparisons while detecting effects under a range of unknown inheritance models. 48 For chrX SNPs, a sex term was added as a covariate and the number of copies of the minor allele was coded as 0 or 2 for males and 0, 1 or 2 for females. Analyses of chrY SNPs were necessarily limited to males.
Control of false discoveries
Given the approximately 500 000 statistical comparisons in a GWAS, highly significant findings (P < 10 À6 ) are expected by chance. To control the risk of false discoveries, q-values 49, 50 were computed for all P-values for single-marker tests of association. A q-value is an estimate of the proportion of false discoveries among all the significant markers. In other words, a q-value is the false discovery rate (FDR) for the corresponding P-value. As argued elsewhere, 51, 52 the use of q-values is preferable to more traditional multiple-testing controls because q-values (1) provide a better balance between the competing goals of finding true-positives and controlling false discoveries; (2) allow more similar comparisons across studies because the proportions of false discoveries are much less dependent on the number of tests conducted; (3) are relatively robust against the effects of correlated tests 49, [53] [54] [55] [56] [57] [58] [59] [60] and (4) provide a more nuanced picture regarding the possible relevance of the tested markers rather than an all-or-nothing conclusion about whether a study produces significant results. The q-value threshold for declaring significance was 0.10, that is, the top 10% of the significant findings were, on an average, allowed to be false discoveries (see studies by van den Oord and Sullivan 51, 56 for a thorough consideration of these issues). FDR thresholds < 0.10 result in a disproportionate decrease in power to detect true effects.
Multimarker analyses
The score test of Schaid et al. 61 implemented in the R (v2.5.1) 62 function 'haplo.score' (v1.3.1) (http://www. cancercenter.mayo.edu/mayo/research/schaid_lab/ software.cfm; v1.3.1 (accessed 28 June 2007)) was used for multimarker association analyses. This test uses unphased genotypes and probabilistic haplotype assignments to estimate haplotype-phenotype association within a given genomic region. Overlapping sliding windows over the genome (500 kb segments plus 200 kb segments centered on boundaries between the 500 kb blocks) were used to estimate linkage disequilibrium (LD) and to form haplotypes via the Gabriel method 63 implemented in HaploView. 64 LD blocks were estimated in European (EUR) subjects, the predominant ancestry group in this sample. The resulting 74 411 haplotypes had a median length of 8.2 kb and an interquartile range of 2.7-20.0 kb. These haplotypes contained 335 539 SNPs (69.23% of all autosomal SNPs) and covered 1.368 gigabases (47.78% of the autosomal genome). As haplotype frequencies differ by ancestry, 65 an assumption of haplo.score-all subgroups share the same haplotype frequencies-was violated. Therefore, GWAS multimarker analyses were run in separate subgroups, and a combined test statistic has been reported. Fisher's method 74 was used to combine lists of P-values for the same SNPs (for example, from different GWAS) or for the same haplotypes (that is, from African (AFR) and EUR subjects in this GWAS). The test statistic for K-independent P-values is
Statistical power
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Project context
A list of completed and proposed genotyping projects using the CATIE samples is available online (https:// www.slep.unc.edu/evidence (downloads tab; accessed 2 October 2007)). Future manuscripts using these GWAS data will investigate copy-number variation and genetic influence on treatment response, tardive dyskinesia and neurocognition. The NIMH controls are being used in several other projects. Table 1 presents descriptive data for cases and controls. Cases and controls were well matched for age and ancestry but not for sex (due to insufficient numbers of African-American males in the control pool, as described in Methods). There were large differences between cases and controls in education, marital status and employment, consistent with the adverse effects of a chronic mental illness with onset in early adulthood. Cases had been ill for a mean of 14 years and the mean PANSS scores 75 were consistent with a moderately ill sample. As described previously, 76 CATIE subjects who provided DNA samples had lower symptom severity (PANSS total 74 vs 77), had lesser current drug/alcohol abuse/dependence (29 vs 36%) and were less likely to describe themselves as African-American (29 vs 40%) in comparison with CATIE subjects who did not provide a DNA sample.
Results

Sample description
SNP description
The analysis SNP set had 492 900 SNPs including 484 664 autosomal SNPs, 8084 SNPs on chrX, 143 SNPs on chrXY/PAR1, 9 SNPs on chrY and 0 SNPs on PAR2 and chrM (mitochondrial DNA). Table 2 depicts summary of missingness and MAF (minor allele frequency) estimates from the GWAS analysis set in the entire sample and separately for cases and controls; on an average, across the genome, SNP missingness appears to be acceptably low. The average marker density over the genome was 1 SNP every 6.2 kb (3 077 088 087 bases/492 900 SNPs). The median intermarker distance was 2.8 kb with an interquartile range of 0.8-7.1 kb and the 99th percentile was 39.7 kb.
Single-marker association tests
We used logistic regression to test for association of the 492 900 SNPs in the GWAS data set with case/ control status (with seven principal components 44 included as covariates to account for population stratification). The minimum P-value obtained was 1. Figure 1 : panel (a) shows the QQ plot 77 for GWAS for case-control status. The QQ plot suggests that the observed P-values do not strongly depart from the Pvalue distribution expected by chance; panel (b) shows the Àlog(P) across the human genome to make spatial clustering evident. To facilitate comparisons with other data sets, inclusion in meta-analyses and further investigation of these findings, all P-values are available in Supplementary Table 2 and the data used to create Figure 1b are contained in Supplementary  Table 3 . SNPs that failed quality control are contained in Supplementary Table 4 .
For an FDR threshold of 0.10, the proportion of all SNPs without true effects (P 0 ) can be estimated from the GWAS results 60 and was found to be P 0 = 0.9999904. This result is consistent with the presence of approximately five SNPs with true effects in these GWAS data for SCZ. q-Values were calculated for all P-values under the conservative assumption that P 0 = 1, and no SNPs reached genomewide significance as the minimum q-values of 0.45 (rs10911902 and rs16977195) did not exceed the prespecified FDR threshold of 0.10 (Table 3) . Nearly identical results were obtained using P 0 = 0.9999904 (data not shown).
Additional data about the SNPs with the 25 smallest P-values are shown in Table 3 . First, the allele frequency differences between CATIE AFR and EUR subjects were generally similar (median difference 0.09, interquartile range 0.05-0.25) suggesting that one precondition for population stratification artifacts was not universally met. Moreover, the SNP with the greatest MAF difference (rs297257, | MAF AFR ÀMAF EUR | = 0.49) yielded similar odds ratio estimates in AFR and EUR subjects (0.73 and 0.71, respectively), despite the allele frequency difference. Second, critically, the odds ratios in Table 3 were generally of similar direction and magnitude for the overall sample (including seven principal components) as well as in logistic regressions without covariates for AFR and EUR subjects separately (note that significance tests were not conducted for the stratified logistic regressions). There was one exception as noted in Table 3 (rs4568102). These findings support the approach to population stratification control used here, and suggest that the overall odds ratios were generally unlikely to be caused by stratification artifacts despite different allele frequencies in subjects of EUR and AFR ancestries.
Third, SNP allele frequencies in CATIE were reassuringly similar to those in the HapMap panels with the possible exception of three chrX SNPs in CATIE AFR subjects. Fourth, some results in Table 3 may be problematic due to the lack of robustness of odds ratio estimates for uncommon alleles (rs4846033, rs4568102, rs16917897, rs16977195 and rs10521865), suboptimal performance of the calling algorithm on manual review (rs1380272, rs16917897 and rs17070578) and differential missingness in cases and controls (rs10521865). The existence of a high LD 'proxy' SNP that also shows association reduces the chance of a false-positive due to genotyping artifact. Fifth, most of the top 25 findings were not located within the transcript of a known gene and, for the 11 genes listed in Table 3 , searches in PubMed and SZGene identified no published studies of SCZ, although prior linkage studies implicated these genomic regions. Sixth, two pairs of SNPs in the top 25 were located near one another and two additional SNPs clustered with over 10 SNPs that were nominally significant and in relatively close proximity. Finally, Table 3 also presents SNP annotations: two SNPs were in copy-number-variant regions, one SNP was modestly conserved, one SNP was in a predicted transfactor-binding site and 17 of the top 25 SNPs were predicted to be in regions with regulatory potential.
Spatial clustering of SNPs with significant associations may be an indication that a genomic region does not represent a spurious finding, particularly if the , where P is the asymptotic P-value from the additive test that the SNP coefficient is 0, i is the rank for each SNP P-value (1 = smallest, L = largest), and L is the number of SNPs. The dashed lines show the expected 95% probability interval for ordered P-values. (b) Depicts Àlog 10 (P) by genomic location. The top 25 SNPs are indicated in green (online only). 
Positive controls and bioinformatic comparisons
It is highly desirable to compare GWAS findings with 'positive controls' (that is, genomic regions with very strong prior evidence for association like APOE*e4 and Alzheimer's disease 79 or FTO/intron 1 and body mass index 15 ). At the time of this writing in October 2007, there were no such regions for SCZ, although there were a few genomic regions with multiple positive but inconsistent findings.
First, the GWAS platform used here had at least 1 SNP in 25 287 'known genes'. 80 The median number of SNPs per gene was 4, interquartile range 2-11 and range 1-1088. The number of SNPs per gene is strongly related to the gene size (Spearman r = 0.79), meaning that larger genes have more SNPs on an average. Second, the GWAS findings were compared with a list of 525 candidate genes for SCZ that had been investigated at least once in a published report (http://www.schizophreniaforum.org/res/sczgene (accessed 28 June 2007)). This list includes studies with positive or negative findings and thus represents candidate genes that at least one set of investigators believed to be relevant to the etiology of SCZ. The number of studies per gene varied widely-from 302 genes studied in single reports to genes that had been studied > 50 times (52 reports for HTR2A, 57 reports for DRD2, 65 reports for DRD3 and 68 reports for COMT). In the GWAS results, there were 534 SNPs with P-values < 0.001 (an arbitrary choice) that implicated 249 genes (1 SNP could be located in multiple genes)-of these, only 6 (2.41%) had been the subject of a prior study (ARMC3, CACNA1A, FEZ1, NRG1, PIWIL2 and VDR). Although a GWAS platform can provide very good or excellent coverage over the genome on average, there may be important candidate genes with suboptimal SNP coverage. Of the 525 candidate genes previously studied in the literature, 84 genes had no SNPs that passed quality control, including 8 genes that had been studied in X10 reports (APOE, CNTF, CYP2D6, DRD1, DRD4, GRIN1, TH and TNF).
Third, we focused more closely on a consensus set of 15 candidate genes for SCZ with the best evidence of association-12 candidate genes were selected from a review, 8 CSF2RA and IL3RA were from a published SCZ GWAS 23 and PLXNA2 was from a large-scale candidate gene study for SCZ 81 (Table 5) . Of the 249 genes with one or more P-values < 0.001 in this GWAS, only 1 was on this list of 15 candidate genes (NRG1). Although the GWAS platform we used had generally good coverage across the genome (1 SNP per 6.2 kb on an average), 6 of these 15 genes had inadequate coverage and 9 genes had SNP densities better than the GWAS average (2.2-5.0 SNPs per kilobase). For this subset of GWAS data, the proportion of SNPs without true effects (P 0 ) 60 was estimated at 0.997 for an FDR threshold of 0.10 and the minimum q-value was 0.30. In comparison with all GWAS SNPs, these results suggest that these candidate regions may be enriched for genetic variants influencing susceptibility to SCZ.
None of the results in Table 5 survive FDR multiple comparison correction. Nonetheless, we investigated a few of these results further (Supplementary Figure 7) . Of the 146 SNPs in the vicinity of DISC1 (minimum P-value 0.001), the significant findings clustered around the chr1 (1;11)(q42;q14.3) translocation break point 13 as follows: rs2738875 (P = 0.001)-5.0 kb-translocation break point-3.0 kb-rs11122342 (P = 0.62)-0.6 kb-rs6672782 (P = 0.016)-0.1 kb-start of haplotype HEP1-0.8 kb-rs11588937 (P = 0.83)-8.6 kb-end of haplotype HEP1-8.0 kb-rs12744978 (P = 0.048). These data are not conclusive, but the locations of the significant DISC1 SNPs coincide very closely with the DISC1 break point 13 and the HEP1 haplotype implicated in the etiology of SCZ 82 and reduced prefrontal cortex graymatter density. 83 Of the 401 SNPs in the vicinity of NRG1 (minimum P-value 0.0009), there were 15 SNPs (6 with P < 0.05 including the most significant NRG1 SNP, rs16879809) in a cluster at the 3 0 end of NRG1. This cluster was 875 kb from the 5 0 portion of NRG1 that has been of particular interest. 9, 84, 85 Three of 53 SNPs in the 'HapIce' haplotype 9 had P-values between 0.01 and 0.05. The SNP rs6994992 84, 85 was not genotyped in this GWAS but had been done in these samples previously: rs6994992 was weakly associated with SCZ but in the opposite direction than has been reported. 86 Of the 13 SNPs in the vicinity of COMT, 2 consecutive exonic SNPs, 1 kb apart, had P = 0.02. These were rs4633 (synonymous) and rs4680 (val158-met), which has been widely studied as a genetic risk factor for SCZ and other disorders. 87 Finally, of the 84 SNPs in the vicinity of PLXNA2, the significant SNPs were 80 kb away from those highlighted in the initial report 81 and whose most notable SNP (rs752016) was not significant in this GWAS (P = 0.90). It is important to stress that none of these findings met genomewide significance and the overlap with prior studies could have been merely due to chance.
Fourth, these findings were compared with the findings of two published GWAS. The Affymetrix 500K 'A' chips were also used in these studies facilitating direct comparisons. For a SCZ GWAS, 23 the list of P-values was not available from the authors but the most significant association was for the PAR1 SNP rs4129148 (P = 3.7 Â 10
À7
). 23 This finding was not replicated in the CATIE GWAS (P = 0.41). Indeed, only 5 of 143 SNPs in the pseudoautosomal region had association P-values < 0.05 (none within 600 kb of rs4129148) and there were no pseudoautosomal region P-values < 0.001. In comparing the CATIE GWAS with the Wellcome Trust bipolar disorder GWAS, 18 the QQ plot for the 370 216 common to both studies is shown in Supplementary Figure 8 . This comparison was motivated by suspicions that SCZ and bipolar disorder might share etiological genetic risk factors; however, there was no substantial divergence of the observed from the expected P-value distributions.
Multimarker analyses
The QQ plot for combined P-values from genomewide multimarker analyses conducted on AFR and EUR subjects is shown in Supplementary Figure 9 ; there was no marked deviation of the observed from the expected P-value distributions. Moreover, there was no overlap of the 12 genes listed in Table 5 or the 525 genes that have been investigated in studies of SCZ with the 100 haplotypes with P < 0.001.
Discussion
The present GWAS for SCZ had multiple notable features. It is the second published GWAS for SCZ, and the first for which all individual genotype and phenotype data were made available to the research community under an 'open-source' philosophy. Moreover, this project was conceptualized from the beginning as a two-stage study. 56, 88 The present report constitutes the first stage and, as anticipated, there are no 'slam-dunk' findings that meet genomewide significance; however, it is exceedingly possible that there exist true findings in these results that may not be impressive in any single study but that only emerge by comparing multiple large GWAS.
It is hoped that the process of gene finding for SCZ will mirror that of type 2 diabetes mellitus (T2DM). In 2006, 3 genes had accumulated strong evidence in support of association-after the publication of six T2DM GWAS in 2007, [18] [19] [20] [21] [22] 89 there are now 8 (and perhaps as many as 11) genes with highly compelling support. 90 Notably, several of the initial T2DM GWAS had QQ plots very similar to that in Figure 1a , 19, 20 and only after 'aggressive data sharing' 22 across studies and additional genotyping in thousands of additional samples did multiple high-confidence findings emerge. 90 Indeed, some of the findings that eventually proved to be highly significant had initial P-value ranks in hundreds or even thousands.
Therefore, these data from the CATIE GWAS will be part of an inclusive meta-analysis of individual phenotype and genotype data from all available SCZ GWAS that will be done in Q1 2008 under the auspices of the Psychiatric GWAS Consortium. It is anticipated that there will be well over 10 000 cases plus controls available for meta-analysis-particularly large-scale projects include the GAIN SCZ Additional notable features of this project include that, at the time genotyping was conducted, the GWAS platform used here had the best genomic coverage for common genomic variation with r 2 X0.8 for 86% of the genome in subjects of European ancestry, 79% for East Asian ancestry and 49% for African ancestry. 92 The CATIE sample was ascertained from diverse sites across the continental United States to accrue a 'real-world' sample of patients in the treatment for chronic SCZ 27 and a rich set of phenotypes are available for all CATIE subjects, that is, treatment response in a randomized, doubleblind clinical trial, 24 multiple assessments of tardive dyskinesia 93 and repeated assessments of neurocognition. 94 The principal finding of the present study was that no SNP or multimarker combination of SNPs achieved genomewide significance. Moreover, there was no important overlap of our findings with those from published GWAS for SCZ 23 or bipolar disorder. 18 However, some findings with uncorrected P-values < 0.05 overlapped with regions of DISC1 and COMT that have been highlighted in prior studies. Of the 146 SNPs in the vicinity of DISC1 (minimum genewise Pvalue 0.001), the significant findings clustered around the chr1 translocation break point 13 and the HEP1 haplotype implicated in the etiology of SCZ 82 and associated with reduced prefrontal cortex gray-matter density. 83 This observation is bedeviling-these statistical signals could easily be due to chance (even the best finding would not survive multiple comparison correction for SNPs in DISC1 alone, much less for the 492 900 SNPs in this GWAS) and yet the location of the signals is intriguing. Whether the observed overlap is merely due to chance 14 or reflects genetic influences on liability to SCZ will require the metaanalyses described above.
There are three broad explanations for the pattern of findings observed in this SCZ GWAS. The first and most optimistic possibility is that there are true findings relevant to the etiology of SCZ imbedded in these results but it will require careful and rigorous comparisons with other GWAS data sets along with additional genotyping in new samples to delineate true from false-positive findings.
Statistical power is a particular concern. The sample size of 738 SCZ cases and 733 group-matched controls and a genomewide set of 492 900 SNPs provided the capacity to detect genetic effects of moderate size for reasonably common polymorphisms (that is, minor allele frequencies exceeding 10%). True genetic effects influencing case-control status might not have been detected in this study for reasons predictable from the design of this study. Non-detection could have occurred if the genotypic effect size was below the detection threshold, the effect was located in a genomic region for which there was poor SNP coverage, the effect was a genetic variant other than an SNP (for example, a copynumber variant) and there was low LD with genotyped SNPs, or in the presence of excessive phenotypic or locus heterogeneity. Additionally, it is possible that true-positive findings could have been obscured by the use of principal components analysis in this heterogeneous sample particularly for SNPs in strongly stratified genomic regions.
The second possibility is that there are true genetic effects for SCZ but assumptions fundamental to GWAS are incorrect. It is possible that the current definitions of SCZ 28, 95 lack validity. If true, attempting to identify genetic variants associated with 'caseness' in a GWAS may prove fruitless as case classifications based on signs and symptoms are poorly correlated with genetic etiological factors. It is possible that the fundamental model is incorrect-GWAS are predicated under the common disease/common variant model where prevalent human diseases are caused by polymorphisms of relatively modest effects. If SCZ is caused by multiple rare variants (causation due to multiple, quite uncommon genetic variants of very strong effect), 96 then the GWAS design is inappropriate to the fundamental genetic phenomenon. It is possible that liability to SCZ is mostly or entirely due to interactions between genomic regions or between genomic regions and environmental factors and these must be explicitly modeled to be detected. Each of these instances provides an explanation why true effects were not detected.
Finally, the least optimistic possibility is that despite the indirect evidence from family, adoption and twin studies, 4 there exist no true genetic effects causal to SCZ. This option does not appear consistent with a sizeable body of genetic epidemiological data; however, data from quasi-experimental studies do not constitute proof of the involvement of specific genetic variants in the etiopathology of SCZ.
It could prove possible to determine which of these three possibilities are operative for SCZ on near horizon. In the meantime, SCZ genetics needs no more false claims 14 -there is an urgent need to identify replicable findings associated with SCZ. Consistent with this belief, these analyses have been interpreted with caution and the individual phenotype and genotype data made available to the scientific community (http://www.nimhgenetics.org (accessed 28 June 2007)).
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